Advertisement
Advertisement
U.S. Markets open in 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

Big Cypress Acquisition Corp. (BCYP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.44-2.01 (-19.23%)
At close: 03:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.45
Open10.46
Bid0.00 x 1100
Ask0.00 x 900
Day's Range8.23 - 12.90
52 Week Range7.30 - 12.90
Volume15,335,164
Avg. Volume2,267,566
Market Cap124.846M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

    Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completio

  • PR Newswire

    Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

    Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs

  • Business Wire

    SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

    SIOUX FALLS, S.D., October 06, 2021--SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

Advertisement
Advertisement